What Zetia Does
Zetia (ezetimibe) lowers cholesterol by blocking its absorption in the small intestine, reducing LDL-cholesterol by approximately 18% as monotherapy and an additional 25% when combined with statins, and has proven cardiovascular benefit in reducing heart attacks, strokes, and cardiovascular death. 1, 2
Mechanism of Action
Ezetimibe works through a unique mechanism distinct from statins:
- Targets the NPC1L1 protein at the brush border of the small intestine, which is the molecular transporter responsible for cholesterol absorption 1, 2
- Blocks absorption of both dietary and biliary cholesterol (cholesterol secreted from the liver into bile), inhibiting approximately 54% of intestinal cholesterol uptake 2
- Does NOT inhibit cholesterol synthesis in the liver or increase bile acid excretion—this complementary mechanism makes it ideal for combination with statins 2
- Reduces delivery of intestinal cholesterol to the liver, causing hepatic cholesterol stores to decrease and increasing clearance of cholesterol from the blood 2
Therapeutic Effects
Lipid Profile Improvements
- LDL-cholesterol: 18% reduction as monotherapy; 25% additional reduction when added to statins 1
- Total cholesterol, ApoB, non-HDL cholesterol: All significantly reduced 1
- HDL-cholesterol: Modest increase 2
- Triglycerides: Moderate reduction 2
Cardiovascular Outcomes
The drug has demonstrated proven cardiovascular benefit in major trials 1:
- IMPROVE-IT trial: When added to moderate-intensity statins in patients with recent acute coronary syndrome, ezetimibe reduced the composite endpoint of cardiovascular death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, or nonfatal stroke over 6 years 1
- SHARP trial: Combined simvastatin plus ezetimibe reduced major atherosclerotic cardiovascular events (nonfatal MI, CHD death, non-hemorrhagic stroke, or arterial revascularization) in patients with chronic kidney disease over 4.9 years 1
Clinical Use According to Guidelines
When to Use Ezetimibe
Primary indication: First-line add-on therapy when maximum tolerated statin therapy fails to achieve LDL-cholesterol goals 3, 1
- Secondary prevention (established cardiovascular disease): Add ezetimibe if LDL-C remains >70 mg/dL on maximum tolerated statin (Class I recommendation, Level A evidence)
- Primary prevention: Add ezetimibe if maximum tolerated statin doesn't achieve >40% LDL-C reduction from baseline after 3 months
- Very high-risk patients: Immediate combination of high-intensity statin with ezetimibe is now recommended for acute coronary syndrome patients to ensure rapid LDL-C goal attainment 3
- Statin intolerance: Ezetimibe serves as alternative monotherapy when statins cannot be tolerated 1, 4
- Elderly patients ≥75 years: The EWTOPIA 75 study supports ezetimibe monotherapy for primary prevention in this age group, as cholesterol absorption efficiency increases with age 5
Dosing and Administration
- Standard dose: 10 mg orally once daily 1
- Can be taken with or without food 1, 2
- Timing with bile acid sequestrants: Take either ≥2 hours before or ≥4 hours after bile acid sequestrants if used in combination 1
Safety Profile
Contraindications and Precautions
- Contraindicated: Hypersensitivity to ezetimibe 1
- Not recommended: Moderate to severe hepatic impairment 1, 2
- Avoid in pregnancy/lactation: No safety data in humans 1
- Monitor liver enzymes when combined with statins, as persistent transaminase elevations may occur 1
- Rare myopathy/rhabdomyolysis reported when used alone or with statins 1
Common Adverse Effects
Monotherapy 1:
- Upper respiratory tract infection
- Diarrhea
- Arthralgia
- Sinusitis
- Pain in extremities
With statin combination 1:
- Nasopharyngitis
- Myalgia
- Upper respiratory tract infection
- Arthralgia
- Diarrhea
Drug Interactions
- Cyclosporine: Significant interaction 1
- Fibrates: Potential interaction 1
- Bile acid sequestrants: Timing adjustment required 1
Key Clinical Advantages
Ezetimibe is generally well tolerated and allows use of lower statin doses when combined, reducing statin-related side effects while enhancing LDL-cholesterol lowering by approximately 20% 4. The percentage of patients achieving target LDL-C <70 mg/dL is higher with statin-ezetimibe combination versus high-intensity statin monotherapy 4.
Generic availability makes it cost-effective compared to newer agents like PCSK9 inhibitors 1, and its oral once-daily dosing is more convenient than injectable alternatives 4.